|
20 Aug 2019 |
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
|
|
20 Aug 2019 |
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
|
|
20 Aug 2019 |
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
|
|
20 Aug 2019 |
Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.
|
|
20 Aug 2019 |
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
|
|
20 Aug 2019 |
Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia
|
|
20 Aug 2019 |
Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
|
|
20 Aug 2019 |
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis
|
|
20 Aug 2019 |
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
|
|
20 Aug 2019 |
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
|
|
20 Aug 2019 |
Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME
|
|
20 Aug 2019 |
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
|
|
20 Aug 2019 |
Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-6219
|
|
20 Aug 2019 |
OKYO Pharma Announces Collaboration with Prof. Pedram Hamrah to Evaluate Proprietary Lead Compounds as Non-Opioid Analgesics Targeting G-Protein Coupled Receptors
|
|
20 Aug 2019 |
Vaxxilon Awarded CARB-X Grant to Advance Novel Prophylactic Vaccine to Prevent Klebsiella pneumoniae Infections
|
|
19 Aug 2019 |
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
|
|
19 Aug 2019 |
On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer
|
|
19 Aug 2019 |
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
|
|
19 Aug 2019 |
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
|
|
19 Aug 2019 |
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
|
